Merus N v   (MRUS)
Other Ticker:  
Price: $51.8200 $3.34 6.889%
Day's High: $52.035 Week Perf: 8.87 %
Day's Low: $ 48.48 30 Day Perf: 45.24 %
Volume (M): 1,064 52 Wk High: $ 52.04
Volume (M$): $ 55,152 52 Wk Avg: $25.34
Open: $48.90 52 Wk Low: $17.15

 Market Capitalization (Millions $) 2,792
 Shares Outstanding (Millions) 54
 Employees -
 Revenues (TTM) (Millions $) 46
 Net Income (TTM) (Millions $) -177
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 12

Merus N V
Merus N is a company that specializes in creating high-quality products for use in the health and wellness industry. They are known for their innovative and unique approach to developing effective solutions for various health concerns.

Merus N focuses on using natural ingredients and advanced scientific research to create their products. They prioritize safety and efficacy, ensuring that their customers receive the best possible results.

Their product range includes dietary supplements, skincare products, and personal care items. These products are formulated to address specific health issues such as immune support, digestive health, stress management, and anti-aging.

Merus N emphasizes the use of sustainable and environmentally friendly practices in their manufacturing processes. They are dedicated to creating products that are both beneficial for consumers and respectful of the planet.

Overall, Merus N is committed to providing high-quality health and wellness solutions that enhance people's lives and promote overall well-being.

   Company Address: Uppsalalaan 17 Utrecht 3584
   Company Phone Number: 016 2500   Stock Exchange / Ticker: NASDAQ MRUS


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Merus N.V.: Pioneering New Hope in EGFRm NSCLC Treatment while Achieving Impressive Revenue Growth

Published Sun, Dec 3 2023 1:40 AM UTC

Merus N.V., a leading clinical-stage immuno-oncology company, recently presented encouraging interim data on its immunotherapy drug MCLA-129 at the prestigious ESMO Asia Congress 2023. The company also reported a remarkable revenue increase during the same period. This article delves into the details of Merus N.V.'s potential breakthrough in treating EGFRm NSCLC an...

Merus N V

Merus N V Experiences Impressive Revenue Surge and Substantial Reduction in Losses, Signaling Strong Growth in the Major Pharmaceutical Preparations Industry

Respectable Revenue Rise for Merus N V in Q3 2023: A Promising Outlook for the Major Pharmaceutical Preparations Industry
In its recently released report for the third quarter of 2023, Major Pharmaceutical Preparations company, Merus N V, showcased an impressive revenue increase of 67.649% to $11.03 million. This growth has not only supported the company in significantly cutting its losses, reducing the loss per share from $-0.53 in the corresponding quarter of the previous year to $-0.43, but it has also positioned Merus N V advantageously within the Major Pharmaceutical Preparations industry.
When compared to its industry peers, Merus N V outperformed them all in terms of revenue improvement during the third quarter of 2023. While its contemporaries recorded a modest 1.30% top-line rise in the same period, Merus N V's growth is undoubtedly commendable. This positive performance signifies a strong market position for the company within the industry.

Merus N V

Merus N.V Reports Increased Losses and Declining Revenue in Q2 2023, Spurring Concerns Over Future Performance

Merus N.V, a prominent pharmaceutical company, recently released its financial results for the fiscal period of April to June 2023. These results indicate a mixed bag of outcomes, with both positive and negative aspects to consider. In this article, we will delve deeper into these figures and assess their potential impact on the company's future prospects.
1. Earnings Per Share (EPS) and Losses:
Merus N.V experienced both progress and setbacks in terms of its EPS. On the positive side, the company managed to improve its EPS from a loss of $-0.86 to $-0.66 per share, compared to the previous reporting period. However, this improvement must be weighed against the fact that, a year ago, the company's EPS stood at only $-0.13 per share. This regression in earnings reflects the need for closer examination of Merus N.V's strategies to reverse this trend.
2. Revenue Performance:
Merus N.V faced a decline in revenue for the April to June 2023 period. The revenue receded by -17.408%, amounting to $10.48 million, compared to $12.68 million during the same reporting period a year ago. Additionally, the sequential revenue decrease from the previous reporting period amounted to -22.394%, reaching $13.50 million. This notable drop in revenue raises concerns about the company's ability to generate consistent income.

Merus N V

Major Pharmaceutical Preparations Company, Merus N V, Witnesses Widened Losses as First Quarter 2023 Earnings Season Unfolds

As an investor, it is important to exercise caution when considering a stock with a cumulative net loss of $-152 million in the 12 months ending in the first quarter of 2023. Merus N V has recorded a negative return on equity (ROE) of -55.8%, which is lower than 51 other companies in the Major Pharmaceutical Preparations industry. It is important to note that while Merus N V's overall ranking has advanced to 1164 from 3414 in the fourth quarter of 2022, the company is still struggling to turn a profitDuring the first quarter of 2023 earnings season, Merus N V increased its deficit per share to $-0.86 from $-0.43 a year prior and from $0.00 per share from the previous financial reporting period. While revenue inched up by 15.822% to $13.50 million from $11.66 million in the corresponding financial reporting period a year prior, sequentially revenue improved by 26.561% from $10.67 million.
It is important to note that Merus N V realized a net deficit of $-39.741 million in the first quarter of 2023, which is bigger than the $-18.893 million of a year ago. Furthermore, the company is expected to report its next financial earnings on May 08, 2023.
In summary, while Merus N V has shown some improvement in its overall ranking, the company is still reporting significant net losses and is suffering from a negative return on equity. As such, investors should exercise caution when considering Merus N V as an investment option. It is important to thoroughly research the company, their financials, and their future plans before making any investment decisions.


Merus N V's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com